<?xml version="1.0" encoding="UTF-8"?><ns2:project xmlns:ns1="http://gtr.rcuk.ac.uk/gtr/api" xmlns:ns2="http://gtr.rcuk.ac.uk/gtr/api/project" xmlns:ns3="http://gtr.rcuk.ac.uk/gtr/api/fund" xmlns:ns4="http://gtr.rcuk.ac.uk/gtr/api/person" xmlns:ns5="http://gtr.rcuk.ac.uk/gtr/api/project/outcome" xmlns:ns6="http://gtr.rcuk.ac.uk/gtr/api/organisation" ns1:created="2026-08-26T13:36:10Z" ns1:href="http://gtr.ukri.org/gtr/api/projects/3D2E1BC2-AA58-427C-9816-46FA043FCBD4" ns1:id="3D2E1BC2-AA58-427C-9816-46FA043FCBD4"><ns1:links><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/persons/217AAD88-4926-449B-8881-5F8E055DA6C9" ns1:rel="PM_PER"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/38016A64-D4C0-43F5-B39B-3E7A5730EB28" ns1:rel="LEAD_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/38016A64-D4C0-43F5-B39B-3E7A5730EB28" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:end="2012-11-30T00:00:00Z" ns1:href="http://gtr.ukri.org/gtr/api/funds/1D715EAF-F3E6-4A00-813F-EF5C7B4EA8BC" ns1:rel="FUND" ns1:start="2012-07-31T23:00:00Z"/></ns1:links><ns2:identifiers><ns2:identifier ns2:type="RCUK">130834</ns2:identifier></ns2:identifiers><ns2:title>Feasibility of Neotherix electrospun scaffolds with additional anti-cancer functionality for regenerative medicine</ns2:title><ns2:status>Closed</ns2:status><ns2:grantCategory>Feasibility Studies</ns2:grantCategory><ns2:leadFunder>Innovate UK</ns2:leadFunder><ns2:abstractText>Neotherix Limited is a regenerative medicine company developing novel bioresorbable scaffolds for soft tissue repair and regeneration. As the number of applications and technologies for regenerative medicine continue to grow, there will be an increasing demand for functional materials that are capable of carrying out multiple roles during tissue repair. For example, novel regenerative scaffolds that deliver drugs to tissues following injury or disease.
This project will explore the feasibility of combining a selection of anti-cancer drugs with Neotherix’ proprietary electrospun scaffold technology to create new advanced regenerative medicine products for therapeutic applications.</ns2:abstractText></ns2:project>